About Fertin Pharma
Fertin Pharma is a Healthcare company based in Vejle (Denmark) founded in 1915, and was acquired by Philip Morris International in July 2021. Medicated chewing gum for pharmaceuticals is developed and manufactured. Fertin Pharma has raised $962.11 thousand across 3 funding rounds from investors including Philip Morris International, EQT and IFU. Its chief executive, as recorded, is Soren Birn. Its Indian entity Fertin India Private Limited reported revenue of ₹31.20 Cr. Fertin Pharma offers products and services including Zapliq®, Compressed gum, Extruded gum, Lozenge, and Pouches. Its focus areas include Life Sciences, Drug Delivery and Diversified.
Company details
Fertin Pharma was established in 1915 in Vejle, Denmark, within the pharmaceutical sector. Medicated chewing gum is developed and produced for various applications, utilizing a patented multi-layered compressed technology known as Medichew. Additional offerings include nutraceuticals, oral care items, multivitamins, and related products, with operations centered on manufacturing and innovation in oral delivery systems.
- Headquarters Vejle, Denmark
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website fertin.com
- Social LinkedIn Facebook
- Acquired by Philip Morris International (Jul 2021)
- Legal Name Fertin Pharma A/S
- Date of Incorporation 25 May, 2013
- Indian entity revenue₹31.20 Cr
FY 2025 · +23% YoY
- Indian entity net loss-₹52.94 Cr
FY 2025 · -170% margin
- Indian entity EBITDA-₹49.30 Cr
FY 2025 · -158% margin
- Total Equity Funding$962.11K (USD)
in 3 rounds
- Latest Funding Round$962.11K (USD), Private Equity Round
Jun 2014
- InvestorsPhilip Morris International
& 3 more
- Acquired by
Associated legal entities of Fertin Pharma
Fertin Pharma operates through Fertin India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Fertin India Private Limited CIN U24233GA2013FTC007857 | Active | 25 May 2013 | Salcete, Goa | ₹31.2 Cr | 95 | 4 | View details |
Products & Services of Fertin Pharma
Fertin Pharma offers a comprehensive portfolio of products and services, including Zapliq®, Compressed gum, Extruded gum, Lozenge, and Pouches.
Liquid-based system for effective pharmaceutical delivery.
Gum format for targeted active ingredient release.
Custom gum for nutraceutical applications.
Dissolvable form for pain and allergy management.
Container for vitamins and supplements delivery.
Chewable option for energy and sleep aids.
Funding Insights of Fertin Pharma
Fertin Pharma has successfully raised a total of $962.11K across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $962.11 thousand completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $962,108
- Total Rounds 3
- Last Round Private Equity Round — $962,108
- First Round $101,400
(Jul 2008)
- Investors Count 2
All 3 funding rounds of Fertin Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | $1.52M | Debt – Conventional | – | – | |
| Jun 2014 | $962,108 | Private Equity Round | – | IFU | – |
| Jul 2008 | $101,400 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Fertin Pharma
Fertin Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Philip Morris International, EQT and IFU.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm | 1967 | ifu.dk | Copenhagen, Denmark | |
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States | ||
Multi-category tobacco products, including cigarettes and heated options, are manufactured. | 1847 | pmi.com | Neuchatel, Switzerland |
Investor details for Fertin Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Fertin India Private Limited (Fertin Pharma)
Fertin India Private Limited is the primary company behind Fertin Pharma. The board of Fertin India Private Limited currently have 3 directors; the longest-serving is Ravi Kumar Seshadri, appointed in 2013. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ravi Kumar Seshadri DIN 03621454 | Managing Director | 10 Jun 2013 | 13 yrs 4 mo | Fertin India Private Limited |
| Michael Henrik Thomsen DIN 08022446 | Director | 14 Dec 2017 | 8 yrs 10 mo | Fertin India Private Limited |
| Lene Frederiksen Lind DIN 09441666 | Director | 20 Dec 2021 | 4 yrs 10 mo | Fertin India Private Limited |
People of Fertin Pharma
33 people are tracked at Fertin Pharma (15 in leadership, 18 in team).
| Name | Role | Group |
|---|---|---|
Soren Birn | CEO | Leadership |
Anna Marie Stenbæk | Senior Principal P&c Business Partner | Leadership |
Jacob Eriksen | Director | Leadership |
Henri Skou | Vice President Operations & Supply Chain | Leadership |
| Vice President, Quality, Regulatory & Clinical Affairs | Leadership | |
Malene Møller Lauridsen | Director, Head Of Business Planning & Data Management | Leadership |
Jeremy J. S. | Plant Director | Leadership |
Robert Bech Sørensen | Head Of Finance | Leadership |
| Managing Director | Leadership | |
Helle Egdal | Vice President | People, Culture & Sustainability | Fertin Pharma A/s | Leadership |
Tobias Vangsgaard Wind | Vice President Bd, Sales & Marketing | Leadership |
Jesper Neergaard | Senior Principal, Head Of IPR | Leadership |
Jette Mølgaard | Executive Assistant To Chief Executive Officer | Leadership |
Christian Bjerre Villadsen | Director, Head Of SFP | Leadership |
Thomas Mørch Klemmensen | Head Of Corporate Project & Strategy Office | Leadership |
Signe From | Sustainability Project Manager | Team |
Gifford E. Rogers III | Principal Packaging Development Engineer | Team |
Lykke Anderson | Laboratory Technician | Team |
Eva Jacobsen | Senior Manager | Team |
Sanne Skov Jensen | Senior Principal Program Manager | Team |
13 more people are available in the full profile.
Complete people profiles for Fertin Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Fertin Pharma
Figures of Fertin India Private Limited, the primary company behind Fertin Pharma, for FY 2025. Revenue was ₹31.20 Cr (+23% year on year). Net loss was -₹52.94 Cr (-170% margin). EBITDA was -₹49.30 Cr (-158% margin). Revenue has grown at a compounded annual rate of +34% over three years and +65% over five years.
- ₹31.20 CrRevenue · FY 2025 · +23% YoY
- -₹52.94 CrNet loss · -170% margin
- -₹49.30 CrEBITDA · -158% margin
- ₹26.17 CrPaid-up capital
- 95Employees (provident fund records)
- +34%Revenue CAGR, 3 years
- +65%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Fertin India Private Limited are on its company page.
Detailed financial statements for Fertin Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Fertin Pharma
5 dated milestones of Fertin Pharma across 106 years, from founding to its latest funding, stage changes and deals.
- Founded Fertin Pharma is founded.
- Funding First funding round of $101K.
- Funding Latest funding round, Private Equity Round, of $962K.
- Exit Acquired by EQT.
- Exit Acquired by Philip Morris International.
Web traffic of Fertin Pharma
The website of Fertin Pharma (fertin.com) receives about 6.3K visits a month and ranks #3,331,029 among all websites worldwide, #4,373 in Biotechnology and Pharmaceuticals.
- Monthly visits6.3K
▲ 8.2% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,331,029
among all websites
- Category rank#4,373
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.8
- Average visit28 sec
- DevicesDesktop 23% · Mobile 77%
Websites whose visitors overlap most with Fertin Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| innate-pharma.com | 100% | 10.5K | #2,074,647 | View details | |
pmcq.qc.ca | pmcq.qc.ca | 100% | – | ||
| trispharma.com | 100% | 9.7K | #2,135,145 | View details | |
| rottendorf-pharma.fr | 99% | View details | |||
| vasudhapharma.com | 99% | 6.7K | #1,818,910 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fertin Pharma
Complete news archive for Fertin Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fertin Pharma
Fertin Pharma was founded in 1915 and raised its 1st funding round 93 years after it was founded.
Fertin Pharma is headquartered in Vejle, Denmark.
Soren Birn is the CEO of Fertin Pharma, as recorded in our data.
Fertin Pharma is a funded company, having raised a total of $962.11K across 3 funding rounds to date. The company's 1st funding round was a Grant of $101.4K, raised on Jul 2008.
The primary company behind Fertin Pharma, Fertin India Private Limited, reported revenue of ₹31.20 Cr for FY 2025, up 23% year on year.
Fertin Pharma was established in 1915 in Vejle, Denmark, within the pharmaceutical sector. Medicated chewing gum is developed and produced for various applications, utilizing a patented multi-layered compressed technology known as Medichew. Additional offerings include nutraceuticals, oral care items, multivitamins, and related products, with operations centered on manufacturing and innovation in oral delivery systems.
Fertin Pharma offers Zapliq®, Compressed gum, Extruded gum, Lozenge, and 2 more products and services.
Fertin Pharma has 4 investors. Key investors include Philip Morris International, EQT, IFU, and Military Health.
Fertin Pharma operates through Fertin India Private Limited.
Yes. Fertin Pharma was acquired by Philip Morris International in July 2021.
The legal entities of Fertin Pharma currently have 4 directors, including Priyanka Pradip Padhye, Ravi Kumar Seshadri, Michael Henrik Thomsen and others.